Stathopoulou Thaleia-Rengina, Kouki Maria, Pypendop Bruno H, Johnston Atholl, Papadimitriou Serafeim, Pelligand Ludovic
1 Clinical Services and Sciences, Royal Veterinary College, Hatfield, UK.
2 Aristotle University of Thessaloniki School of Veterinary Medicine, Thessaloniki, Greece.
J Feline Med Surg. 2018 Aug;20(8):704-710. doi: 10.1177/1098612X17727234. Epub 2017 Sep 12.
Objectives The objective of this study was to evaluate the analgesic effect and absorption of buprenorphine after buccal administration in cats with oral disease. Methods Six adult client-owned cats with chronic gingivostomatitis (weighing 5.1 ± 1.1 kg) were recruited for a randomised, prospective, blinded, saline-controlled, crossover study. Pain scores, dental examination, stomatitis score and buccal pH measurement were conducted on day 1 under sedation in all cats. On day 2, animals were randomised into two groups and administered one of the two treatments buccally (group A received buprenorphine 0.02 mg/kg and group B received 0.9% saline) and vice versa on day 3. Pain scores and food consumption were measured at 30, 90 and 360 mins after the administration of buprenorphine. Blood samples were taken at the same time and plasma buprenorphine concentration was measured by liquid chromatography-mass spectrometry. Data were statistically analysed as non-parametric and the level of significance was set as P <0.05. Results There were no major side effects after buprenorphine administration. Buccal pH values ranged between 8.5 and 9.1 and the stomatitis disease activity index between 10 and 22 (17.8 ± 4.5), with the scale ranging from 0-30. The maximum buprenorphine plasma concentration (14.8 ng/ml) was observed 30 mins after administration and there was low inter-individual variability. There was a significant difference between baseline pain scores compared with pain scores after buprenorphine ( P <0.05), and between the saline and buprenorphine group at 30 mins ( P = 0.04) and 90 mins ( P = 0.04). There was also a significant effect of the stomatitis index on the pain score. Regarding the pharmacokinetic parameters, cats with stomatitis showed lower bioavailability and shorter absorption half-life after buccal administration of buprenorphine compared with normal cats in previous studies. Conclusions and relevance Buccal administration of buprenorphine in cats with gingivostomatitis produces an analgesic effect and low inter-individual variability in plasma concentration, and it can be incorporated in their multimodal analgesia plan.
目的 本研究的目的是评估丁丙诺啡经颊给药对患有口腔疾病的猫的镇痛效果及吸收情况。方法 招募6只成年客户拥有的患有慢性龈口炎的猫（体重5.1±1.1千克）进行一项随机、前瞻性、盲法、生理盐水对照的交叉研究。在第1天对所有猫进行镇静状态下的疼痛评分、牙科检查、口炎评分及颊部pH测量。在第2天，将动物随机分为两组，经颊给予两种治疗之一（A组给予丁丙诺啡0.02毫克/千克，B组给予0.9%生理盐水），并在第3天交换给药。在给予丁丙诺啡后30、90和360分钟测量疼痛评分和食物摄入量。同时采集血样，采用液相色谱-质谱法测量血浆丁丙诺啡浓度。数据进行非参数统计分析，显著性水平设定为P<0.05。结果 给予丁丙诺啡后未出现重大副作用。颊部pH值在8.5至9.1之间，口炎疾病活动指数在10至22之间（17.8±4.5），范围为0至30。给药后30分钟观察到丁丙诺啡血浆浓度最高（14.8纳克/毫升），个体间变异性较低。基线疼痛评分与丁丙诺啡给药后的疼痛评分之间存在显著差异（P<0.05），生理盐水组和丁丙诺啡组在30分钟（P=0.04）和90分钟（P=0.04）时也存在显著差异。口炎指数对疼痛评分也有显著影响。关于药代动力学参数，与先前研究中的正常猫相比，患有口炎的猫经颊给予丁丙诺啡后生物利用度较低，吸收半衰期较短。结论及相关性 丁丙诺啡经颊给药对患有龈口炎的猫产生镇痛效果，血浆浓度个体间变异性较低，可纳入其多模式镇痛方案。
